These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 23830474)

  • 21. Committee Opinion No. 604: OnabotulinumtoxinA and the bladder.
    Obstet Gynecol; 2014 Jun; 123(6):1408-1411. PubMed ID: 24848923
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Re: Urinary Retention Rates after Intravesical OnabotulinumtoxinA Injection for Idiopathic Overactive Bladder in Clinical Practice and Predictors of this Outcome.
    Wein AJ
    J Urol; 2016 Mar; 195(3):685-6. PubMed ID: 26887727
    [No Abstract]   [Full Text] [Related]  

  • 23. Pharmacotherapy for overactive bladder: minimally invasive treatment -- botulinum toxins.
    Apostolidis A
    Expert Opin Pharmacother; 2011 May; 12(7):1029-39. PubMed ID: 21288184
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Botulinum toxin A for the Treatment of Overactive Bladder.
    Hsieh PF; Chiu HC; Chen KC; Chang CH; Chou EC
    Toxins (Basel); 2016 Feb; 8(3):. PubMed ID: 26938559
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Botulinium toxin and idiopathic overactive bladder: Multicentric contempory management in Bourgogne].
    Schneider A; Tourlonias B; Cormier L; Mourey E; Koutlidis N; Delorme E; Pasquale J; Kermarec I; Foahom-Kamwa AD; Bonniaud V
    Prog Urol; 2018 Mar; 28(3):173-179. PubMed ID: 29329897
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chapter 4: Guidelines for the diagnosis and treatment of overactive bladder (OAB) and neurogenic detrusor overactivity (NDO).
    Nambiar A; Lucas M
    Neurourol Urodyn; 2014 Jul; 33 Suppl 3():S21-5. PubMed ID: 25042139
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An overview of treatment of overactive bladder syndrome in women.
    Allahdin S; Oo N
    J Obstet Gynaecol; 2012 Apr; 32(3):217-21. PubMed ID: 22369391
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intradetrusor onabotulinumtoxinA injection: how I do it.
    Shenot PJ; Mark JR
    Can J Urol; 2013 Feb; 20(1):6649-55; discussion 6655. PubMed ID: 23433140
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tips and Tricks in Intra-Detrusor Botulinum Toxin A (BoNTA) Injections.
    Corcos J; Biardeau X; Aharony S
    World J Urol; 2015 Jun; 33(6):899-901. PubMed ID: 26217823
    [No Abstract]   [Full Text] [Related]  

  • 30. A new treatment for overactive bladder.
    Mayo Clin Health Lett; 2013 Jul; 31(7):4. PubMed ID: 24712053
    [No Abstract]   [Full Text] [Related]  

  • 31. Long-Term Treatment with OnabotulinumtoxinA Results in Consistent, Durable Improvements in Health Related Quality of Life in Patients with Overactive Bladder.
    Ginsberg DA; Drake MJ; Kaufmann A; Radomski S; Gousse AE; Chermansky CJ; Magyar A; Nicandro JP; Nitti VW;
    J Urol; 2017 Oct; 198(4):897-904. PubMed ID: 28536084
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sacral Neuromodulation is Preferred over OnabotulinumtoxinA Injection for Overactive Bladder in Women: Pro.
    Kraus SR
    J Urol; 2017 Sep; 198(3):501-502. PubMed ID: 28751015
    [No Abstract]   [Full Text] [Related]  

  • 33. Sacral Neuromodulation is Preferred over OnabotulinumtoxinA Injection for Overactive Bladder in Women: Con.
    Bales GT
    J Urol; 2017 Sep; 198(3):500-501. PubMed ID: 28751016
    [No Abstract]   [Full Text] [Related]  

  • 34. The effect of onabotulinumtoxinA according to site of injection in patients with overactive bladder: a systematic review and meta-analysis.
    Jo JK; Kim KN; Kim DW; Kim YT; Kim JY; Kim JY
    World J Urol; 2018 Feb; 36(2):305-317. PubMed ID: 29124347
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial.
    Dmochowski R; Chapple C; Nitti VW; Chancellor M; Everaert K; Thompson C; Daniell G; Zhou J; Haag-Molkenteller C
    J Urol; 2010 Dec; 184(6):2416-22. PubMed ID: 20952013
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of low doses of onabotulinumtoxinA for the treatment of refractory idiopathic overactive bladder: a multicentre, double-blind, randomised, placebo-controlled dose-ranging study.
    Denys P; Le Normand L; Ghout I; Costa P; Chartier-Kastler E; Grise P; Hermieu JF; Amarenco G; Karsenty G; Saussine C; Barbot F;
    Eur Urol; 2012 Mar; 61(3):520-9. PubMed ID: 22036776
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Botulinum toxin A for idiopathic overactive bladder in women].
    Hampel C
    Urologie; 2024 Jul; 63(7):658-665. PubMed ID: 38922399
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Durable Efficacy and Safety of Long-Term OnabotulinumtoxinA Treatment in Patients with Overactive Bladder Syndrome: Final Results of a 3.5-Year Study.
    Nitti VW; Ginsberg D; Sievert KD; Sussman D; Radomski S; Sand P; De Ridder D; Jenkins B; Magyar A; Chapple C;
    J Urol; 2016 Sep; 196(3):791-800. PubMed ID: 27038769
    [TBL] [Abstract][Full Text] [Related]  

  • 39. OnabotulinumtoxinA improves urodynamic outcomes in patients with neurogenic detrusor overactivity.
    Rovner E; Dmochowski R; Chapple C; Thompson C; Lam W; Haag-Molkenteller C
    Neurourol Urodyn; 2013 Nov; 32(8):1109-15. PubMed ID: 23389824
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Practical aspects of the use of botulinum toxin in the treatment of idiopathic overactive bladder].
    Szczypior M; Matuszewski M
    Wiad Lek; 2018; 71(4):888-892. PubMed ID: 30099430
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.